Cara Therapeutics tried to misdirect investors away from the failure of its osteoarthritis pain pill by burying negative results from a mid-stage clinical trial in the middle of a press release issued Thursday night. The ploy didn’t work. Cara shares plunged, with the stock trading down 30 percent to $17.99 this morning.

The lesson here: Read those clinical trial press releases slowly and carefully! Don’t get bamboozled.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Another lesson in how companies spin is when they set the bar so low, i.e., calling it a “safety study,” then go p-hacking/cherry picking for something positive to report. Worse still are fudged data.

  • Not necessarily negative. The results show they are on the right track but need to try a higher dose. 5 mg dose compared to other meds is still low. Foolish downgrade IMO

Sign up for our Biotech newsletter — The Readout

Your daily guide to what’s new in biotech.

X